Research

An evolved ribosome-inactivating protein targets and kills human melanoma cells in vitro and in vivo

Melissa C Cheung^1,2 , Leigh Revers³ , Subodini Perampalam³ , Xin Wei³ , Reza Kiarash³ , David E Green^4,5 , Aws Abdul-Wahid³ and Jean Gariépy^1,2,3

¹  Department of Pharmaceutical Sciences, University of Toronto, 144 College Street, Toronto, ON, M5S 3 M2, Canada

²  Imaging Research, Sunnybrook Research Institute, 2075 Bayview Avenue, Toronto, ON, M4N 3 M5, Canada

³  Department of Medical Biophysics, University of Toronto, 610 University Avenue, Toronto, ON, M5G 2 M9, Canada

⁴  STTARR Innovation Centre, Radiation Medicine Program, Princess Margaret Hospital, University Health Network, 101 College Street, Toronto, ON, M5G 1L7, Canada

⁵  Department of Radiation Physics, Radiation Medicine Program, Princess Margaret Hospital, University Health Network, 610 University Avenue, Toronto, ON, M5G 2 M9, Canada

author email corresponding author email

Molecular Cancer 2010, 9:28doi:10.1186/1476-4598-9-28

Published:	3 February 2010

Abstract

Background

Few treatment options exist for patients with metastatic melanoma, resulting in poor prognosis. One standard treatment, dacarbazine (DTIC), shows low response rates ranging from 15 to 25 percent with an 8-month median survival time. The development of targeted therapeutics with novel mechanisms of action may improve patient outcome. Ribosome-inactivating proteins (RIPs) such as Shiga-like Toxin 1 (SLT-1) represent powerful scaffolds for developing selective anticancer agents. Here we report the discovery and properties of a single chain ribosome-inactivating protein (scRIP) derived from the cytotoxic A subunit of SLT-1 (SLT-1A), harboring the 7-amino acid peptide insertion IYSNKLM (termed SLT-1A^IYSNKLM) allowing the toxin variant to selectively target and kill human melanoma cells.

Results

SLT-1A^IYSNKLM was able to kill 7 of 8 human melanoma cell lines. This scRIP binds to 518-A2 human melanoma cells with a dissociation constant of 18 nM, resulting in the blockage of protein synthesis and apoptosis in such cells. Biodistribution and imaging studies of radiolabeled SLT-1A^IYSNKLM administered intravenously into SCID mice bearing a human melanoma xenograft indicate that SLT-1A^IYSNKLM readily accumulates at the tumor site as opposed to non-target tissues. Furthermore, the co-administration of SLT-1A^IYSNKLM with DTIC resulted in tumor regression and greatly increased survival in this mouse xenograft model in comparison to DTIC or SLT-1A^IYSNKLM treatment alone (115 day median survival versus 46 and 47 days respectively; P values < 0.001). SLT-1A^IYSNKLM is stable in serum and its intravenous administration resulted in modest immune responses following repeated injections in CD1 mice.

Conclusions

These results demonstrate that the evolution of a scRIP template can lead to the discovery of novel cancer cell-targeted compounds and in the case of SLT-1A^IYSNKLM can specifically kill human melanoma cells in vitro and in vivo.